Treatment of acne with local application of Unani medicine.
- Conditions
- Health Condition 1: L700- Acne vulgaris
- Registration Number
- CTRI/2022/06/042981
- Lead Sponsor
- Jamia Hamdard
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
The following patients will be included in the study
1) Subjects with any of the following lesions of
Basoor Labaniyah: comedones, papules, pustules,
nodules associated with itching and erythema.
2) Clinically stable patients.
3) Patients of both genders in age groups of 13 to 40 years.
4) Patients willing to sign the informed consent
form and participate in the trial voluntarily.
5) Patients with moderate to severe acne (score of
acne 19-38), as per the Global Acne Grading
System (GAGS).
1)Pregnant and lactating women.
2)Women using hormonal contraceptives.
3)Patients suffering from PCOD on the basis
Ultrasound and LH: FSH ratio.
4)Patients with chronic systemic disorders
like pulmonary, liver, kidney, or heart
disease etc.
5)Patients have had chemical or laser peel
and artificial UV therapy.
6)Patient using medications that are
reported to exacerbate acne.
7)Patients suffering from other concomitant
skin diseases like acne fulminans, acne
necrotica, psoriasis, eczema etc.
8)Patients who have used isotretinoin in the
last six months and systemic antibiotic
within past one month.
9)Patients who have used topical anti-acne
medications within past two weeks.
10)Any confluent nodule, cyst present.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in GAGS Scale Score <br/ ><br>Reduction in CADI Score <br/ ><br> <br/ ><br>Timepoint: Day 1, Day 14, Day 28, Day 42, Day 56 <br/ ><br>
- Secondary Outcome Measures
Name Time Method Improvement in Likert Scale for itching, erythema and scarringTimepoint: Day 1, Day 14, Day 28, Day 42, Day 56